Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.

Production 133

Production Bioavailability In-Vivo In-Vitro 133

XTalks

JANUARY 6, 2021

Related: Scientists Use Llama Antibodies to Neutralize COVID-19. Nanobodies are attractive therapeutic agents because of their small size and simple structure, which allow them to be more easily used as templates to design antibody drugs compared to human antibodies. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Pharmaceutical Technology

JANUARY 6, 2023

It requires having access to proper techniques and skill sets, state-of-the-art equipment, process scientists and engineers who have a deep understanding of Quality by Design (QbD) principles, and methods for product and process characterisation. Expertise in analytical testing, validation, and quality control are also essential.

Production 130

Production Manufacturing Development Bioequivalency 130

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. 3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and sustainability. Who Should Attend?

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

XTalks

APRIL 6, 2022

Scientists at the University of Cambridge evaluated the use of a personalized blood test that detects ctDNA to help predict the relapse risk of lung cancer. The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Photo source: Inivata.

DNA 105

DNA In-Vitro Doctors Doctor 105

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all. .”

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

pharmaphorum

NOVEMBER 1, 2022

Don’t miss this unmissable opportunity to network with the pharma and biotech community of global experts in the UK and Europe; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

FDA Law Blog

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 42 U.S.C. §

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

The Pharma Data

MAY 15, 2023

Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop. These efforts will also enable early testing of which drug candidates are safe and which molecules would work best for each patient.

In-Vitro 40

In-Vitro Medicine Scientist Development 40

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccine Vaccination Antibody 52

The Pharma Data

MAY 3, 2021

Included were articles on the mid-career transition from research scientist to regulatory professional, continuous professional development and the value of graduate-level qualifications, and findings from two surveys on different aspects of the profession. Continuous professional development. Who is the average regulatory professional?

Development 52

Development Contamination In-Vitro Production 52

The Pharma Data

NOVEMBER 1, 2020

Food and Drug Administration (FDA). The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor Plus System to be delivered in The Netherlands by mid-November. THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , The first 1.2 million units will be delivered by mid-November.

In-Vitro 52

In-Vitro Production Protein Scientist 52

XTalks

SEPTEMBER 20, 2024

Such challenges highlight a significant unmet need and call for further advancements in the field. Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

The Pharma Data

NOVEMBER 12, 2021

”For decades, this has remained a major challenge for scientists because our body’s central nervous system, which includes the brain and spinal cord, doesn’t have any significant capacity to repair itself after injury or after the onset of a degenerative complaint. The exploration will be published in theNov.

Engineer 40

Engineer In-Vitro Medicine Scientist 40

pharmaphorum

JANUARY 22, 2021

The mutations identified in these new variants have not significantly altered the part of the virus that remdesivir targets or have any association with known mutations conferring reduced susceptibility of coronaviruses to remdesivir in vitro,” said Gilead in its statement. “We The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

Pharma Mirror

APRIL 21, 2024

Scientists have been striving to optimize mRNA stability, immunogenicity, translation efficiency, and delivery systems to achieve efficient and safe mRNA delivery. In vitro transcribed (IVT) mRNA has been successfully The post General Design Methods for mRNA Drugs appeared first on Pharma Mirror Magazine.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. Pfizer’s COVID-19 therapy Paxlovid, for example, targets Mpro.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

pharmaphorum

JULY 6, 2022

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by diagnostics to quickly identify pathogens and their resistance patterns and guide treatment.

In-Vitro 59

In-Vitro Development Pharma Companies Drugs 59

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. The drug is a once-daily, beta-3 adrenergic agonist. Here’s a look. Urovant Sciences’ Vibegron for Overactive Bladder.

In-Vitro 52

In-Vitro FDA Approval Drugs Manufacturing 52

Roots Analysis

OCTOBER 19, 2023

The overuse of antibiotics has resulted in the emergence of multi-drug-resistant bacteria. Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ).

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Research 130

Research Clinical Trials Clinical Trials Trials 130

pharmaphorum

NOVEMBER 4, 2020

Most of the trials are underpowered to demonstrate efficacy on mortality and long-term consequences of the disease… It is not surprising there is no recommended drug treatment for COVID-19, except dexamethasone and remdesivir, despite little evidence that this drug reduces mortality”.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Vaccine 105

XTalks

MARCH 11, 2021

As a novel virus, public health experts, scientists and clinicians faced challenges in how to effectively prevent its transmission, and how to best treat it in the most severe cases. After its identification in late 2019, COVID-19 was officially declared a pandemic by the World Health Organization (WHO) on March 11, 2020. COVID-19 Treatments.

Vaccine 98

Vaccine Vaccination In-Vitro Antibody 98

FDA Law Blog

NOVEMBER 8, 2022

To put it into perspective, these were the numbers (so far) for in vitro diagnostics EUAs: 304 molecular, 84 antibody, 51 antigen, and 5 other. Below, we provide a snapshot of the three-day event: Update on the International Medical Device Regulators Forum (IMDRF). In response, Ms. This includes EUAs and full marketing authorizations.

Regulation 59

Regulation In-Vitro Production Marketing 59

XTalks

SEPTEMBER 14, 2020

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92